82261-42-5

Basic information

• Product Name: 4-(3-PYRIDYL)ANILINE
• Synonyms: 4-(3-PYRIDYL)ANILINE;4-PYRIDIN-3-YL-PHENYLAMINE;4-PYRIDIN-3-YL-PHENYLAMINE DIHYDROCHLORIDE;4-PYRIDIN-3-YLANILINE;2-Pyridyl-4-aniline;3-(4-Aminophenyl)pyridine;4-(3-Pyridinyl)aniline;4-(3-Pyridinyl)benzenamine
• CAS NO: 82261-42-5
• Molecular Formula: C₁₁H₁₀N₂
• Molecular Weight: 170.21
• EINECS: 1533716-785-6
• Product Categories: pharmacetical
• Mol File: 82261-42-5.mol
• Article Data: 33

Chemical Properties

• Melting Point: 115 °C
• Boiling Point: 333℃
• Flash Point: 182℃
• Appearance: /
• Density: 1.133
• Vapor Pressure: 0.00014mmHg at 25°C
• Refractive Index: 1.625
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(3-PYRIDYL)ANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-PYRIDYL)ANILINE(82261-42-5)
• EPA Substance Registry System: 4-(3-PYRIDYL)ANILINE(82261-42-5)

Safety Data

• Hazard Codes: Xi
• Statements: 20/21/22-36/37/38
• Safety Statements: 26-36/37/39-22
• Hazardous Substances Data: 82261-42-5(Hazardous Substances Data)

Usage

General Description

4-(3-Pyridyl)aniline, also known as 3-pyridyl-4-aminobenzene, is a chemical compound with the molecular formula C11H10N2. It is a pale yellow to beige solid that is commonly used as a building block in the synthesis of various pharmaceuticals, agrochemicals, and dyes. 4-(3-Pyridyl)aniline is a versatile intermediate in organic synthesis, as it can be used to create a wide variety of compounds with diverse properties. It is also a potential environmental contaminant and has been studied for its potential toxic effects on human health and the environment. Overall, 4-(3-Pyridyl)aniline is a useful and versatile chemical compound with a range of potential applications.

InChI:InChI=1/C11H10N2/c12-11-5-3-9(4-6-11)10-2-1-7-13-8-10/h1-8H,12H2

Upstream product

• 4282-46-6 3-(4'-nitrophenyl)pyridine 
• 82261-44-7 3-(4-dimethylureidophenyl)pyridine 
• 89878-14-8 3-Diethylboranylpyridine 
• 106-40-1 4-bromo-aniline 
• 626-55-1 3-Bromopyridine 
• 89415-43-0 (4-aminophenyl)boronic acid 
• 33976-43-1 para-aminophenyltrimethoxysilane 
• 1008-88-4 3-phenylpyridine 
• 110-86-1 pyridine 
• 150-68-5 monuron 
• 3408-97-7 N'-(4-bromophenyl)-N,N-dimethylurea 
• 1692-25-7 3-pyridylboronic acid 
• 220565-63-9 pyridin-3-ylzinc(II) bromide 
• 540-37-4 p-aminoiodobenzene 

Downstream Products

• 113182-91-5 N-(4-propoxy-phenyl)-N'-(4-[3]pyridyl-phenyl)-thiourea 
• 124138-25-6 N-(4-butoxy-phenyl)-N'-(4-[3]pyridyl-phenyl)-thiourea 
• 1008-88-4 3-phenylpyridine 
• 68223-13-2 4-(pyridin-3-yl)phenol 
• 215527-54-1 2,6-dibromo-4-(pyridin-3-yl)aniline 
• 215527-56-3 N-[(4-nitrophenyl)thio]-2,6-diphenyl-4-(3-pyridyl)aniline 
• 215527-57-4 N-[(2,4-dichlorophenyl)thio]-2,6-diphenyl-4-(3-pyridyl)aniline 
• 445012-62-4 4-(pyridin-3-yl)benzene-1,2-diamine 
• 167959-19-5 2-nitro-4-(pyridin-3-yl)benzenamine 
• 154164-36-0 4-(3-pyridyl)acetanilide 
• 85633-41-6 5-(3-pyridyl)salicylaldehyde 

Relevant articles and documents

Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CLpro)

Starting from the MLPCN probe compound ML300, a structure-based optimization campaign was initiated against the recent severe acute respiratory syndrome coronavirus (SARS-CoV-2) main protease (3CLpro). X-ray structures of SARS-CoV-1 and SARS-CoV-2 3CLpro enzymes in complex with multiple ML300-based inhibitors, including the original probe ML300, were obtained and proved instrumental in guiding chemistry toward probe compound 41 (CCF0058981). The disclosed inhibitors utilize a noncovalent mode of action and complex in a noncanonical binding mode not observed by peptidic 3CLpro inhibitors. In vitro DMPK profiling highlights key areas where further optimization in the series is required to obtain useful in vivo probes. Antiviral activity was established using a SARS-CoV-2-infected Vero E6 cell viability assay and a plaque formation assay. Compound 41 demonstrates nanomolar activity in these respective assays, comparable in potency to remdesivir. These findings have implications for antiviral development to combat current and future SARS-like zoonotic coronavirus outbreaks.

NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF

The present invention relates to novel hydrazone derivatives in which a terminal amine group is substituted with an aryl group or a heteroaryl group, and uses thereof.

Novel hydrazone derivatives comprising aryl or heteroaryl group substituted at terminal amine and use thereof

The present invention relates to novel hydrazone derivatives with an aryl or heteroaryl group substituted at a terminal amine group thereof and a use thereof.